Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

118 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.
Hughes DA, Bagust A, Haycox A, Walley T. Hughes DA, et al. Health Econ. 2001 Oct;10(7):601-15. doi: 10.1002/hec.609. Health Econ. 2001. PMID: 11747044 Review.
A review of pharmacoeconomic evaluations, which have applied sensitivity analysis to non-compliance rates, was undertaken to evaluate the impact of non-compliance on the cost-effectiveness of different drug therapies. ...However, it was evident that non-compliance always r
A review of pharmacoeconomic evaluations, which have applied sensitivity analysis to non-compliance rates, was undertaken to evaluate
The cost effectiveness of metal oesophageal stenting in malignant disease compared with conventional therapy.
Nicholson DA, Haycox A, Kay CL, Rate A, Attwood S, Bancewicz J. Nicholson DA, et al. Clin Radiol. 1999 Apr;54(4):212-5. doi: 10.1016/s0009-9260(99)91153-4. Clin Radiol. 1999. PMID: 10210338
A difference was identified between the length of survival in both patient groups and the analysis was corrected for this by estimating a cost per day of palliative support. ...However, once this was corrected for survival the difference in the cost of palliation on
A difference was identified between the length of survival in both patient groups and the analysis was corrected for this by estimati
Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
Wladysiuk M, Araszkiewicz A, Godman B, Szabert K, Barbui C, Haycox A. Wladysiuk M, et al. Appl Health Econ Health Policy. 2011 Mar 1;9(2):101-10. doi: 10.2165/11318840-000000000-00000. Appl Health Econ Health Policy. 2011. PMID: 21271749
The reverse was seen with risperidone, with only limited growth in utilization when co-payment levels increased.Market forces resulted in a 40% reduction in the reimbursed reference price (based on the defined daily dose) of olanzapine and a 77% reduction for risper …
The reverse was seen with risperidone, with only limited growth in utilization when co-payment levels increased.Market forces resulted in …
Systematic review of cost effectiveness studies of telemedicine interventions.
Whitten PS, Mair FS, Haycox A, May CR, Williams TL, Hellmich S. Whitten PS, et al. BMJ. 2002 Jun 15;324(7351):1434-7. doi: 10.1136/bmj.324.7351.1434. BMJ. 2002. PMID: 12065269 Free PMC article. Review.
Only 24/55 (44%) studies met quality criteria justifying inclusion in a quality review. 20/24 (83%) restricted to simple cost comparisons. ...CONCLUSION: There is no good evidence that telemedicine is a cost effective means of delivering health care....
Only 24/55 (44%) studies met quality criteria justifying inclusion in a quality review. 20/24 (83%) restricted to simple cost compari …
Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.
Haycox A. Haycox A. Pharmacoeconomics. 2005;23 Suppl 1:3-16. doi: 10.2165/00019053-200523001-00002. Pharmacoeconomics. 2005. PMID: 16416758 Review.
Long-acting risperidone is a new formulation of an atypical antipsychotic agent that combines the pharmacological advantages of the atypical drugs with those of its mode of administration. ...A discrete event simulation (DES) model that was developed using UK cost a …
Long-acting risperidone is a new formulation of an atypical antipsychotic agent that combines the pharmacological advantages of the a …
Cost effectiveness of asthma treatment with a breath-actuated inhaler: how has the story changed?
Haycox A, Featherstone R. Haycox A, et al. J Med Econ. 2008;11(3):525-39. doi: 10.3111/13696990802340856. J Med Econ. 2008. PMID: 19450102
Furthermore, the introduction of specific targets for asthma review included a requirement for regular checks on inhaler technique. ...METHODS: As in all chronic diseases, it is important that economic analyses evaluate cost effectiveness over as long a period as po …
Furthermore, the introduction of specific targets for asthma review included a requirement for regular checks on inhaler technique. . …
Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
Parker M, Haycox A, Graves J. Parker M, et al. Pharmacoeconomics. 2011 Aug;29(8):719-30. doi: 10.2165/11588360-000000000-00000. Pharmacoeconomics. 2011. PMID: 21635017
OBJECTIVE: The objective of this study was to examine the extent to which disease-specific measures generated in the clinical trials for a new treatment for chronic constipation (prucalopride) can be 'mapped' onto a preference-based generic measure (EQ-5D and SF-6D) …
OBJECTIVE: The objective of this study was to examine the extent to which disease-specific measures generated in the clinical trials for …
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Haycox A, Armand C, Murteira S, Cochran J, François C. Haycox A, et al. Drugs Aging. 2009;26(9):791-801. doi: 10.2165/11316770-000000000-00000. Drugs Aging. 2009. PMID: 19728752
METHODS: An economic Markov model was developed as a pragmatic tool to derive comparative information on the effectiveness, utility and costs of these two strategies over a 5-year period. ...CONCLUSIONS: Rasagiline represents a cost-effective alternative to p …
METHODS: An economic Markov model was developed as a pragmatic tool to derive comparative information on the effectiveness, utility a …
Optimizing decision making and resource allocation in palliative care.
Haycox A. Haycox A. J Pain Symptom Manage. 2009 Jul;38(1):45-53. doi: 10.1016/j.jpainsymman.2009.04.009. J Pain Symptom Manage. 2009. PMID: 19615626
In such circumstances, we can either adjust cost-effectiveness thresholds to ensure that end-of-life interventions have a less stringent cost-effectiveness hurdle to overcome or we can derive an entirely new evaluative framework that better captures the true value of inter …
In such circumstances, we can either adjust cost-effectiveness thresholds to ensure that end-of-life interventions have a less string …
Utility assessment of HIV/AIDS-related health states in HIV-infected Ugandans.
Lara AM, Wakholi BN, Kasirye A, Munderi P, Watera C, Lalloo DG, Haycox A, Gilks CF, Grosskurth H. Lara AM, et al. AIDS. 2008 Jul;22 Suppl 1:S123-30. doi: 10.1097/01.aids.0000327633.85221.9a. AIDS. 2008. PMID: 18664944
Deterioration in health status was associated with a reduction in rating scores (VAS), increased willingness to give up time (TTO) and acceptance of increased risk (SG) to achieve a better health state, independent of the participant's actual health state, as measur …
Deterioration in health status was associated with a reduction in rating scores (VAS), increased willingness to give up time (TTO) an …
118 results
Jump to page
Feedback